Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort - 16/01/21
, Jean-Michel Correas b, 1, Celine Dorival c, Fabien Zoulim d, Albert Tran e, Marc Bourlière f, Paul Calès g, Dominique Guyader h, Jean-Pierre Bronowicki i, Dominique Larrey j, Christophe Hezode k, Veronique Loustaud-Ratti l, Jerome Gournay m, Victor de Ledinghen n, Tarik Asselah o, Nathalie Ganne p, Sophie Metivier q, Olivier Chazouillères r, Vincent Leroy s, Isabelle Rosa t, Didier Samuel u, Philippe Mathurin v, Carole Cagnot w, Helene Fontaine a, Fabrice Carrat c, Stanislas Pol aAFEF ANRS study group
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 10 |
| Iconographies | 3 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | Our blinded analysis of HCC recurrence following “curative” treatment: |
• | Argues against the “curative” efficacy of the first treatment of HCC in one third of patients. |
• | Evidences that DAA therapy has no significant impact on the severity or progression of HCC recurrence. |
• | Evidences that DAA therapy does not impact overall survival and could be considered in cirrhotic patients with prior history of HCC. |
Summary |
Background |
Although it has now been excluded that direct-acting antivirals (DAA) are associated with a significant risk of hepatocellular carcinoma (HCC) in HCV-infected patients, a possible effect of DAA on tumor growth is still a subject of debate. We performed a blind comparison of the kinetics of HCC recurrence in patients after HCV treatment with or without DAA to evaluate the potential aggressiveness of HCC after DAA treatment.
Basic procedures |
Thirty-nine HCV-infected patients from the AFEF/ANRS CO22 Hepather cohort who experienced HCC recurrence after so-called curative treatment were evaluated. Contrast-enhanced CT and/or MR images were read blindly 6 months before HCC recurrence and during the follow-up period. Seventeen patients who received DAA (DAA+) before HCC recurrence were compared to the 22 who did not receive (DAA−), according to the LiRads and mRECIST criteria.
Main findings |
There were 28 men and 11 women, median age 62 years old, 37 (95%) with cirrhosis. DAA+ patients had a lower median MELD score (8±2 vs. 10±4, P=0.0286) than DAA− patients. The median time to HCC recurrence (time from the date of curative treatment to the diagnosis of recurrence) was not different (20 vs. 18 months) (P=0.73) between the two groups. There was no difference between the 2 groups in the overall survival and/or transplantation-free survival (P=0.71) and for the mRECIST time to progression (P=0.25).
Conclusion |
This blinded analysis of HCC recurrence after HCC treatment does not support any negative impact of DAA therapy on the severity or progression of recurrent HCC.
Le texte complet de cet article est disponible en PDF.Keywords : Direct-acting antivirals, Hepatitis C virus, Hepatocellular carcinoma recurrence, Tumor growth
Abbreviations : DAA, HCC, AFEF, ANRS, LT, CT, MR, mRECIST, TACE, SVR, BCLC
Plan
Vol 45 - N° 1
Article 101459- janvier 2021 Retour au numéro
Article précédent
- Real life experience of mycophenolate mofetil monotherapy in liver transplant patients
- Guillaume Lassailly, Jerome Dumortier, Franck Saint-Marcoux, Medhi El Amrani, Juliette Boulanger, Emmanuel Boleslawski, Guillaume Millet, Massih Ningarhari, Stephanie Truant, Valérie Canva, Odile Goria, Olivier Boillot, Alexandre Louvet, Philippe Mathurin, Gilles Lebuffe, François-René Pruvot, Pierre Marquet, Sébastien Dharancy
- Combining cellular immunotherapy was an optional choice for unresectable advanced HCC: A systematic review and meta-analysis
- Jing Wang, Lingxin Feng, Linwei Zhang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?